Von Willebrand Diseases
1
Pipeline Programs
3
Companies
4
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
OctapharmaAustria - Vienna
3 programs1
WilatePhase 31 trial
Use of a postpartum diary and additional blood drawsN/A1 trial
Von Willebrand Factor-Containing ProductN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
OctapharmaWilate
OctapharmaUse of a postpartum diary and additional blood draws
OctapharmaVon Willebrand Factor-Containing Product
TakedaATHN 9: Severe VWD Natural History Study
Clinical Trials (4)
Total enrollment: 317 patients across 4 trials
Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD
Start: Jun 2020Est. completion: Apr 202243 patients
Phase 3Completed
Von Willebrand Factor in Pregnancy (VIP) Study
Start: Oct 2019Est. completion: Dec 2026110 patients
N/ARecruiting
Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment
Start: Jun 2019Est. completion: Jan 202156 patients
N/ACompleted
ATHN 9: Severe VWD Natural History Study
Start: Jun 2019Est. completion: Jul 2026108 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 317 patients
3 companies competing in this space